Animal Models of Complement-Mediated Hypersensitivity Reactions to Liposomes and Other Lipid-Based Nanoparticles
暂无分享,去创建一个
Miklós Tóth | M. Tóth | C. Alving | J. Szebeni | L. Rosivall | R. Bünger | János Szebeni | Carl R Alving | László Rosivall | Rolf Bünger | Lajos Baranyi | Péter Bedöcs | Yezheckel Barenholz | L. Baranyi | Y. Barenholz | Péter Bedöcs
[1] S. de Marie. Liposomal and lipid-based formulations of amphotericin B. , 1996, Leukemia.
[2] F. Ligler,et al. Biological responses to exchange transfusion with liposome-encapsulated hemoglobin. , 1992, Circulatory shock.
[3] J. Szebeni. The Complement System , 2004, Springer US.
[4] M. Bodó,et al. The interaction of liposomes with the complement system: in vitro and in vivo assays. , 2003, Methods in enzymology.
[5] M. Woodle,et al. Long Circulating Liposomes: Old Drugs, New Therapeutics , 1998, Biotechnology Intelligence Unit.
[6] J. Szebeni,et al. The interaction of liposomes with the complement system. , 1998, Critical reviews in therapeutic drug carrier systems.
[7] W. Lorenz,et al. Histamine release in dogs by Cremophor El® and its derivatives: Oxethylated oleic acid is the most effective constituent , 1977, Agents and Actions.
[8] G. Feuerstein,et al. Characterization of hemodynamic, hematologic, and biochemical responses to administration of liposome-encapsulated hemoglobin in the conscious, freely moving rat. , 1989, Circulatory shock.
[9] J. Uetrecht,et al. Role of animal models in the study of drug-induced hypersensitivity reactions , 2005, The AAPS Journal.
[10] D. Tzemach,et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma , 2000, Cancer.
[11] J Szebeni,et al. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. , 1999, Circulation.
[12] L J Liang,et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J Szebeni,et al. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. , 2001, International immunopharmacology.
[14] J. Szebeni. The complement system : novel roles in health and disease , 2004 .
[15] H. Lutz,et al. The Role of Complement Activation in Hypersensitivity to Pegylated Liposomal Doxorubicin (Doxil®) , 2000 .
[16] J. Szebeni. Complement Activation-Related Pseudoallergy , 2004 .
[17] F M Muggia,et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] J. V. Von Roenn,et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] F M Muggia,et al. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. , 1998, Journal of the National Cancer Institute.
[20] J. Hainsworth,et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] M. Bodó,et al. Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. , 2006, American journal of physiology. Heart and circulatory physiology.
[22] T. Yue,et al. Biological responses to liposome-encapsulated hemoglobin (LEH) are improved by a PAF antagonist. , 1990, Circulatory shock.
[23] Y. Barenholz,et al. Clinical studies of liposome-encapsulated doxorubicin. , 1994, Acta oncologica.
[24] A. Giatromanolaki,et al. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] D. Pode,et al. Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer , 2000, Anti-cancer drugs.
[26] A. Brody,et al. Pulmonary intravascular macrophages produce prostaglandins and leukotrienes in vitro. , 1988, Chest.
[27] J. Codina,et al. Sch-28080 depletes intracellular ATP selectively in mIMCD-3 cells. , 2000, American journal of physiology. Cell physiology.
[28] M. Olausson,et al. Prevention of acute lung injury in swine: depletion of pulmonary intravascular macrophages using liposomal clodronate. , 2003, The Journal of surgical research.
[29] A. Hershey,et al. Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumors. , 2004, Journal of veterinary internal medicine.
[30] A. Gabizon,et al. Initial Clinical Evaluation of Pegylated-Liposomal Doxorubicin in Solid Tumors , 1998 .
[31] Thomas Bieber,et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. , 2004, The Journal of allergy and clinical immunology.
[32] R. Pieters,et al. Murine models of drug hypersensitivity , 2005, Current opinion in allergy and clinical immunology.
[33] J. Weaver,et al. Clinical relevance of preclinical testing for allergic side effects. , 2005, Toxicology.
[34] F. Blecha,et al. Porcine Alveolar and Pulmonary Intravascular Macrophages: Comparison of Immune Functions , 1991, Journal of leukocyte biology.
[35] C. Alving,et al. Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation. , 1994, Biochemical and biophysical research communications.
[36] M. Bodó,et al. Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. , 2000, American journal of physiology. Heart and circulatory physiology.
[37] M. Bodó,et al. Complement-Dependent Shock and Tissue Damage Induced by Intravenous Injection of Cholesterol-Enriched Liposomes in Rats , 2003 .
[38] S. Marie. Liposomal and lipid-based formulations of amphotericin B , 1996 .
[39] J. Szebeni,et al. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents. , 2001, Critical reviews in therapeutic drug carrier systems.
[40] F M Muggia,et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] J. Ostensen,et al. Intravenous injection of Albunex microspheres causes thromboxane mediated pulmonary hypertension in pigs, but not in monkeys or rabbits. , 1992, Acta physiologica Scandinavica.